Involvement of the Immune System in Intrinsic Radiosensitivity

Condition(s) studied

Investigational drug(s) / intervention(s)

Blood samples: We propose to include patients who have been treated with radiotherapy and did not experience severe radiation-induced toxicity, after obtaining their informed consent. A blood sample will then be collected by the nursing staff from the Oncology-Radiotherapy department at Henri Mondor University Hospital. After the patient signs the consent form, each patient will have their clinical information recorded and a blood sample taken. The blood samples will be immediately transported, at room temperature, to the INSERM U955 i-Biot unit at Henri Mondor (serum, plasma, and PBMC). All samples will be frozen at -80°C for later analysis.

Study summary

Radiotherapy is one of the major treatments for cancer. It may be indicated in more than two-thirds of patients, regardless of cancer location or disease stage. The mechanisms of radiotherapy action are numerous: halting tumor proliferation, inducing tumor cell death, triggering anti-tumor immune responses, and ensuring both local and systemic tumor control. As a result, current treatments are highly effective, providing, for instance, a 5-year overall survival rate of about 90%-95% for localized breast and prostate cancers.

Eligibility

Primary outcome measure(s)

• Identify immunological markers predictive of intrinsic radiosensitivity. — 48 hours
  Identification of immunological markers predictive of intrinsic radiosensitivity using flow cytometry analysis

Trial sites (1)

More Assistance Publique - Hôpitaux de Paris trials in France

Other trials for the same condition